The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis
Primary Purpose
Sepsis, Hyperglycemia, Critical Illness
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SGC directed glycemic control
Sponsored by
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria:
- Admitted to the ICU
- At least one BG measurement 9.0mmol/L or higher
- Expected to stay in ICU ≥3 days;
- critically ill patients with sepsis
- SOFA score≤2
Exclusion Criteria:
- Aged < 18 years;
- Admitted because of diabetic ketoacidosis or nonketotic hyperosmolar state
- Pregnant
- In a state in which death was perceived as imminent
- Without written informed consent
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
conventional empirical glycemic control
Arm Description
the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
Outcomes
Primary Outcome Measures
glucose variability
mean blood glucose, standard deviation (SD) for the mean glucose,minimum and maximum glucose levels
Secondary Outcome Measures
HLADr
Full Information
NCT ID
NCT02980588
First Posted
November 17, 2016
Last Updated
November 29, 2016
Sponsor
Southeast University, China
1. Study Identification
Unique Protocol Identification Number
NCT02980588
Brief Title
The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis
Official Title
Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Sepsis in ICU
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Unknown status
Study Start Date
December 2016 (undefined)
Primary Completion Date
May 2017 (Anticipated)
Study Completion Date
September 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Southeast University, China
4. Oversight
5. Study Description
Brief Summary
Poorly glycemic control in critically ill patients can increase their mortality, while safe and efficient glucose control is laborious and time-consuming. The Space Glucose Control which is installed with eMPC(enhanced Model Predictive Control) can get the blood glucose target range safely and effectively through regulating insulin dose rate, and decrease the glucose variability. This study is a random controlled trial involving the patients with sepsis in intensive care unit in order to evaluate the difference of safety and efficacy of blood glucose control between SGC directed and conventional treatment. At last, the trial results can determine whether the Space Glucose Control can control blood glucose safely and effectively in the patients with sepsis in intensive care units.
Detailed Description
Design: The study was conducted as a single-centre, open randomized controlled, parallel trial.
Study population: Adult general ICU patients with sepsis and assumed to require at least 3 days of intensive care were recruited. Patients fulfilling the inclusion criterion of glucose≥9.0 mmol/L were randomly assigned using serially numbered to either the intervention group (BG control by SGC) or the control group (conventional empiric BG management). The both group aim to establish the BG levels 5.8-8.9mmol/L.
Study protocol: BG measurements were performed using glucometer to test the fingertip capillary blood sample for the BG levels. As for patients with shock or required vasopressor, arterial BG was sampled to measure through the glucometer. Insulin was infused intravenously applying the standard perfusor of the ICU. Average glucose, glucose variability, SOFA score, APACHE II score, and HLA-DR were recorded. All trial-related activities were carried out until the end of the patient's ICU stay, or for a period of 72 hours. Meanwhile, enteral and parenteral nutrition was administrated to patients according to their condition.
Statistical analysis was performed on an intention-to-treat basis. The percentage of values in the target range (5.8-8.9mmol/L) was defined as primary end point for the assessment of glucose control. Data are reported as mean±SD values if not otherwise indicated. Data analysis was performed using SPSS19.0.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Hyperglycemia, Critical Illness
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
conventional empirical glycemic control
Arm Type
Other
Arm Description
the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
Intervention Type
Device
Intervention Name(s)
SGC directed glycemic control
Intervention Description
the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
Primary Outcome Measure Information:
Title
glucose variability
Description
mean blood glucose, standard deviation (SD) for the mean glucose,minimum and maximum glucose levels
Time Frame
up to 3days
Secondary Outcome Measure Information:
Title
HLADr
Time Frame
up to 3days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Admitted to the ICU
At least one BG measurement 9.0mmol/L or higher
Expected to stay in ICU ≥3 days;
critically ill patients with sepsis
SOFA score≤2
Exclusion Criteria:
Aged < 18 years;
Admitted because of diabetic ketoacidosis or nonketotic hyperosmolar state
Pregnant
In a state in which death was perceived as imminent
Without written informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Min Mo, Doctor
Phone
13914719904
Email
momin_2002@163.com
12. IPD Sharing Statement
Learn more about this trial
The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis
We'll reach out to this number within 24 hrs